Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
about
Immunomodulation in sepsis: state of the art and future perspectiveThe Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial DiseaseTargeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseasesA quantitative comparison of single-dye tracking analysis tools using Monte Carlo simulationsAn unusual dimeric structure and assembly for TLR4 regulator RP105–MD-1Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targetsBartonella quintana lipopolysaccharide (LPS): structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applicationsEvidence of a specific interaction between new synthetic antisepsis agents and CD14.Toll-like receptor 4 and hepatic fibrogenesisPartially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses.TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediatedAmelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.Therapeutic interventions in sepsis: current and anticipated pharmacological agentsEritoran: the evidence of its therapeutic potential in sepsisThe role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis.Lead increases lipopolysaccharide-induced liver-injury through tumor necrosis factor-alpha overexpression by monocytes/macrophages: role of protein kinase C and P42/44 mitogen-activated protein kinase.Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?Novel drugs targeting Toll-like receptors for antiviral therapy.Modeling Human Respiratory Viral Infections in the Cotton Rat (Sigmodon hispidus).Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.Recent developments in the identification of novel therapeutic targets for the treatment of patients with sepsis and septic shock.From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxinsPharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in RatsSynthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae.Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.Inflammation--a new therapeutic target in pneumonia.Update on toll-like receptor-directed therapies for human diseaseDNA-Containing Immunocomplexes Promote Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14+ CD16+ CD64high CD32low Inflammatory Monocytes from Malaria Patients.Energetics of Endotoxin Recognition in the Toll-Like Receptor 4 Innate Immune Response.Mechanisms of Toll-like Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by Pathogenic and Commensal Bacteria.Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?Toll-like Receptors in the Vascular System: Sensing the Dangers Within.Selection, synthesis, and anti-inflammatory evaluation of the arylidene malonate derivatives as TLR4 signaling inhibitorsTLR4 signaling mediates inflammation and tissue injury in nephrotoxicity.Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter?Dysregulation of human Toll-like receptor function in aging.Cbl-b is a critical regulator of macrophage activation associated with obesity-induced insulin resistance in mice.The TLR4 antagonist Eritoran protects mice from lethal influenza infection.Protective effects of Sparstolonin B, a selective TLR2 and TLR4 antagonist, on mouse endotoxin shock
P2860
Q22305766-BA1BCC6D-F239-4A94-B0BC-BD377AF58F55Q26753079-8AA19D57-E304-485B-956B-621B71ADD723Q27010345-48F91F6B-6C01-449F-9744-5FC569A468A5Q27319086-50FB6F60-9ED9-4C15-BD65-A7A605586578Q27671851-977144CC-72E1-4EF6-9852-F8A9890D11B3Q28077955-04E78A62-08A2-4E59-BB4F-7E58A58D1570Q28828935-5616CE2B-3FEC-4311-A38F-951B2F6E0784Q33575108-BDD4F0B6-6ADD-4171-BFBE-10681768C8CBQ33905721-2D8FF819-4454-43AE-8403-4EE21658D731Q33954358-A33503ED-64A5-4115-A58B-C929DB7F7394Q34107852-38D66743-DD3A-4AB3-A599-32001C3D1FE5Q34131121-882994EB-A349-4F37-B1E8-A0150FAAE085Q34427050-D106ADA0-7FCA-4085-92CF-F7C234759259Q34449865-087BAAFB-9316-4C9D-B8FA-10F799DD606DQ34461296-8354ED26-CF46-4EEF-92DE-8CD94BDD10D4Q34547090-7882A8AE-8BE9-410E-9609-78EBFB5CAFFCQ34726541-D7B47604-A8CD-4D3C-812F-00F55E1AD19BQ34956130-A0BFCD73-3EAA-4673-B9B4-1273E6FFAB01Q34999938-B59BB25C-2979-4574-A3BF-FC4699631F90Q35017599-291ACBFB-06C5-4CA0-8C53-89051E3BB87BQ35192812-7A21979D-ACB3-44B4-A8FA-F2755BA350A9Q35585111-6CCB4636-134A-4C10-A492-429D498257A8Q35657133-937A34EF-629E-4DFE-A975-379DBBA930B9Q35702671-4FBC8FD7-6BED-4A69-94B2-1E3B775CBD8DQ35784146-20812B3D-7256-4E9F-8A22-EE68E97F9A2DQ35981265-E518F6DC-91DC-4F3A-B909-731C69299C3EQ36095647-6F90F167-9CA3-4CE3-B1EE-2231FE462913Q36171745-0924DEC5-42E7-4089-BBB1-3D1018E2B199Q36318958-3E1FF2D2-69C5-4311-94DA-8485E98A512AQ36357406-363A1402-1895-4B71-80A0-F5D51722F66EQ36388377-C49F187E-0125-46FA-A918-12EF6DD2E1DDQ36421502-9C587A3E-8192-4FE7-B39C-58393EA83100Q36453194-07493AB5-852E-441F-BC29-D3A7DBF0DA9FQ36453211-23A9CE48-9A3B-407B-AC32-22DB10CA53B4Q36662114-F45E31C4-CA80-4A95-B2A0-62E9339DE8F6Q36787173-EA840269-64D0-4BF6-8411-CC1880365C45Q36787810-D4C45192-02C8-46FE-ABD0-1B9649513359Q36867563-2CC8A747-7C88-4E35-8C87-2CB8C344A23CQ37051987-7AAA5A3C-C578-4D08-9441-3F3A1D5168C2Q37108130-7E1AD125-877A-4604-BAC5-78EEDE64E8F7
P2860
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@ast
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@en
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@nl
type
label
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@ast
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@en
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@nl
prefLabel
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@ast
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@en
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@nl
P2093
P356
P1476
Inhibition of endotoxin respon ...... directed endotoxin antagonist.
@en
P2093
Akufumi Kimura
Daniel P Rossignol
Fabian Gusovsky
Jeffrey R Rose
Jesse Chow
John Bristol
Maureen Mullarkey
Melinda Przetak
Seiichi Kobayashi
Tsutomu Kawata
P304
P356
10.1124/JPET.102.044487
P407
P577
2003-03-01T00:00:00Z